secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vivani Medical, Inc. (VANI)
CIK:        0001266806
Form:       8-K
Filed at:   2024-05-13T23:59:59+00:00
Accession:  0001753926-24-000957
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vivani Medical Q1 net loss $6.0M, cash $31.0M; NPM-115 IND on track for H2 2024
-------------------------------------------------------------------------------

- Net loss of $6.0M in Q1 2024 vs $6.3M in Q1 2023; cash $31.0M at March 31, 2024, up from $22.0M.
- Completed $15M registered direct offering in March 2024, extending cash runway into H2 2025.
- NPM-115 IND submission on track for H2 2024; first-in-human trial planned after regulatory clearance.
- Positive preclinical data: NPM-115 showed ~20% weight loss in mice, comparable to semaglutide.
- Appointed Daniel Bradbury to Board; he led Amylin's development of first once-weekly GLP-1 Bydureon.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1266806/000175392624000957/0001753926-24-000957-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1266806/000175392624000957/g084237_8k.htm
  HTML page:      https://secwatch.observer/filing/0001753926-24-000957

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer